Latest Conference Articles

Radium-223 in mCRPC showed long-term favorable safety, low second primary malignancies/fracture rates, and consistent overall survival.

EBC-129 demonstrates early activity and manageable safety in patients with heavily pretreated pancreatic cancer, supporting further development.

Patritumab deruxtecan did not improve overall survival compared to chemotherapy in EGFR-mutated NSCLC, despite showing PFS and ORR benefits previously.

Nivolumab plus ipilimumab showed activity in mCRPC, and while adding SBRT was safe, it did not boost efficacy in the CheckPRO trial.

The ANZUP 1301 trial showed that BCG and mitomycin showed similar DFS to BCG alone in NMIBC, but with 40% fewer BCG doses and similar safety.

Extended follow-up of MonumenTAL-1 shows talquetamab-tgvs yields durable ORRs and promising survival outcomes in relapsed/refractory multiple myeloma, with a tolerable safety profile.

Shlomo Koyfman, MD, discusses the MK-3475-630/​KEYNOTE-630 trial, which focused on patients with high-risk cutaneous squamous cell cancer.

Ribociclib combined with aromatase inhibitors shows significant survival benefits for early-stage hormone receptor-positive breast cancer, enhancing treatment outcomes across patient demographics.

T-DXd plus pertuzumab significantly extended PFS (40.7 vs 26.9 months) in HER2+ metastatic breast cancer, suggesting a new frontline standard of care.

The SACHI trial showed savolitinib + osimertinib significantly improved PFS (8.2 vs 4.5 months) vs chemotherapy in EGFR-mutated, MET-amplified advanced NSCLC after EGFR TKI progression.

EMBER-3 trial results show imlunestrant, alone or with abemaciclib, improves patient-reported outcomes for ER+/HER2- advanced breast cancer after endocrine therapy.

The NeoSTAR trial showed neoadjuvant sacituzumab govitecan and pembrolizumab achieved a 32% pCR rate in early-stage TNBC, with promising efficacy and a tolerable safety profile.

Sevabertinib demonstrated high and durable objective response rates in pretreated and treatment-naive HER2-mutant NSCLC, with a manageable safety profile.

A randomized phase 2 study of a GSK-3ß inhibitor plus gemcitabine/nab-paclitaxel showed survival benefit in patients with untreated metastatic pancreatic ductal adenocarcinoma.

An updated 4-year analysis indicates nivolumab/relatlimab offers comparable PFS and OS to nivolumab/ipilimumab in advanced melanoma, with lower toxicity.

Amivantamab plus chemotherapy significantly improved PFS and ORR in EGFR-mutated NSCLC patients resistant to osimertinib, regardless of resistance mechanisms.

Luspatercept significantly improved red blood cell transfusion independence duration and overall survival in ESA-naive, lower-risk MDS patients vs epoetin alfa.

Adagrasib plus pembrolizumab improved efficacy in KRAS G12C-mutant NSCLC, according to data from the KRYSTAL-7 trial.

Dose adjustments enabled longer NALIRIFOX exposure and survival in select metastatic PDAC patients, with favorable clinical profiles despite multiple metastatic sites.

Fruquintinib plus camrelizumab, paclitaxel liposome, and nedaplatin showed a 68.4% ORR and acceptable safety in advanced ESCC.

At ASCO 2025, Suneel Kamath, MD, presented an analysis of federal cancer research funding disparities and their ripple effects on care delivery and outcomes.

Camizestrant plus CDK4/6 inhibition improved progression-free survival when given to patients with ESR1-mutant ER+/HER2– breast cancer in the SERENA-6 trial.

Neoadjuvant PAXG led to a significant improvement in event-free survival vs mFOLFIRINOX in resectable or borderline resectable pancreatic ductal adenocarcinoma.

Adjuvant nivolumab offered sustained survival benefits in resected esophageal/GEJ cancer post chemoradiation, with PD-L1 emerging as a potential biomarker.

Nivolumab with cisplatin and radiotherapy improved disease-free survival in high-risk locally advanced squamous cell carcinoma of the head and neck in the NIVOPOSTOP trial.

Durvalumab plus FLOT improved event-free survival vs placebo in resectable gastric/GEJ cancer.

In the phase 3 PANOVA-3 trial, patients who underwent tumor-treating fields therapy had extended overall survival vs standard-of-care gemcitabine plus nab-paclitaxel.

A 3-year structured exercise program significantly improved DFS and OS in stage II/III CRC, reducing recurrence by 28% and death risk by 37%.

Less inflammatory diets were linked to improved overall survival in stage III colon cancer, and physical activity showed synergistic benefits.